產(chǎn)品分類導(dǎo)航
CPHI制藥在線 資訊 Pharma Sources Insight第四期:復(fù)盤抗疫之年,破局產(chǎn)業(yè)未來

Pharma Sources Insight第四期:復(fù)盤抗疫之年,破局產(chǎn)業(yè)未來

來源:CPhI制藥在線
  2023-04-28
本期Pharma Sources Insight將與制藥人士一起復(fù)盤,盤點(diǎn)2020年**行業(yè)、生物類似藥、國產(chǎn)生物藥的發(fā)展及GMP監(jiān)管趨勢(shì)。

       進(jìn)入2021,觀其形勢(shì),疫情將繼續(xù)在全球范圍內(nèi)受到普遍關(guān)注,過去一年,疫情對(duì)制藥行業(yè)的影響幾何?中國及全球**研發(fā)究竟到了怎樣的階段?隨著**的到來,制藥行業(yè)未來的發(fā)展又將導(dǎo)向何方?

       站在新的起點(diǎn),本期Pharma Sources Insight將與制藥人士一起復(fù)盤,盤點(diǎn)2020年**行業(yè)、生物類似藥、國產(chǎn)生物藥的發(fā)展及GMP監(jiān)管趨勢(shì);同時(shí)立足藥物研發(fā)的前沿,探索2021年制藥行業(yè)在腫瘤**、人工智能等領(lǐng)域的潛在發(fā)展方向,使世界專業(yè)人士更了解中國的藥物審批與藥企發(fā)展?fàn)顩r,為藥企未來的發(fā)展注入新的活力。

       本期內(nèi)容也將向您展示與CPhI制藥在線合作的品質(zhì)供應(yīng)商,同時(shí)也是CPhI & P-MEC China的展商所帶來的特色產(chǎn)品——浙江江北藥業(yè)有限公司原料藥產(chǎn)品,以及上海東富龍科技股份有限公司無菌溶媒結(jié)晶原料藥系統(tǒng)。PharmaSources.com始終致力于向國際市場(chǎng)推介中國本土合作伙伴提供的解決方案,幫助業(yè)內(nèi)人士在抗疫之年,降低采購成本,滿足企業(yè)采購需求。

       新的一年,作為制藥行業(yè)專業(yè)的垂直型B2B貿(mào)易平臺(tái),PharmaSources.com將秉持誠意集結(jié)制藥行業(yè)內(nèi)資深的新作者,提供更高品質(zhì)的原創(chuàng)內(nèi)容,打破疫情時(shí)期國際貿(mào)易的障礙,賦能制藥行業(yè)向縱深發(fā)展。歡迎有意向攜手制藥在線國際站PharmaSources.com及Pharma Sources Insight進(jìn)行品牌推廣的企業(yè),留言咨詢合作詳情

Pharma Sources Insight

January 2021

       Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the pharma industry, from China to the world. It follows up new developments with the leading drug-manufacturers in China which further affect the world.

       Now, join PharmaSources.com to get access to news of the Chinese pharmaceutical enterprises and to witness industrial changes through the exclusive perspectives of our expert writers into crucial aspects of the pharmaceutical field, all under PharmaSources.com and CPhI China.

       Contents:

       Pharma Sources Insight January 2021 focuses on the following topics:

       PHARMA IN CHINA

       - Analysis of the Regulatory Inspection Trends of China, the U.S. and the EU in the Pandemic Year and Outlook Therefor

       - Biosimilars 2020: Low Approvals, but Significant Advances

       - Chinese-produced Anticancer Drugs Granted Designations by the FDA in 2020

       - A Brief Preview of 2021 in the Pharmaceutical Industry

       COVID-19

       - A Brief Overview of COVID-19 Pandemic in 2020

       - Chinese Vaccines Going Global amid Receipt of the COVID-19 Vaccines Worldwide

       - Notable Vaccines Against COVID-19 Making Promising Progress

       - Rolling Out the Vaccines

       Brand Story

       - Sterile Solvent Crystallization API Systems

       Industry Insight

       - Advancing Oncology

Pharma Sources Insight
Pharma Sources Insight 第四期

Your FREE source of news and insights into China pharmaceutical industry,

and more!

Pharma Sources Insight 第四期二維碼

掃碼開始閱讀

Scan to view the full contents.

Previous Review

Pharma Sources Insight第三期

第三期 https://flbook.com.cn/c/73ABnLNFKK

第二期

       第二期 https://flbook.mwkj.net/c/xm1raTzeBd

第一期

       第一期 https://flbook.com.cn/c/5GrJTeke2j

相關(guān)文章

合作咨詢

   肖女士    021-33392297    Kelly.Xiao@imsinoexpo.com

2006-2024 上海博華國際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號(hào)-57